MedTrace Logo

SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial

NCT00578526 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2018-08-22

No results posted yet for this study

Summary

The purpose of this study is to find out if SU011248 works and if it is safe in patients with advanced transitional cell carcinoma.

Conditions

Interventions

DRUG

SU011248

50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression

DRUG

Placebo

50 mg capsule OD PO for 28 days then 14 days rest until disease progression

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • AHS Cancer Control Alberta

    lead OTHER

Principal Investigators

  • Tina Cheng, M.D. · Tom Baker Cancer Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2014-07-16
Completion
2014-07-16

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00578526 on ClinicalTrials.gov